Correspondence 0001493152-24-003025 from Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences, Inc.
Date: Jan. 19, 2024 · CIK: 0000890821 · Accession: 0001493152-24-003025

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276473

Date

January 22, 2024

Author

Chief

Form

CORRESP

Company

Enveric Biosciences, Inc.

Letter

RE: Enveric Biosciences, Inc.

January 19, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-3

(File No. 333-276473)

Acceleration Request

Requested Date: January 22, 2024

Requested Time: 4:30 p.m., Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”) requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Bradley J. Wyatt of Dickinson Wright PLLC at (734) 623-1905 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
Enveric Biosciences, Inc.

Show Raw Text

CORRESP
1
filename1.htm

January
19, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    RE:
    Enveric
    Biosciences, Inc.

    Registration
    Statement on Form S-3

    (File
    No. 333-276473)

Acceleration
Request

Requested
Date: January 22, 2024

Requested
Time: 4:30 p.m., Eastern Time

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”)
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities
and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth
above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation
Finance of the Commission.

Please
call Bradley J. Wyatt of Dickinson Wright PLLC at (734) 623-1905 to confirm the effectiveness of the Registration Statement or with any
questions.

    Very truly yours,

    Enveric Biosciences, Inc.

    By:
    /s/
    Joseph Tucker

    Name:
    Joseph
    Tucker, PhD

    Title:
    Chief
    Executive Officer

SecProbe.io